netFormulary Oxfordshire Clinical Commissioning Group NHS
Formulary  
 Search
 Formulary Chapter 8: Malignant disease and immunosuppression - Full Chapter
08.01.05  Expand sub section  Other antineoplastic drugs
Alectinib (Alecensa®)
View adult BNF View SPC online View childrens BNF
Formulary
NHS England

Red Traffic Light For untreated ALK-positive advanced non-small-cell lung cancer as per NICE TA536. 

Funded by specialised commissioning.

APCO September 2018.

Black Traffic Light For previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer (NICE TA438 - terminated appraisal). 

APCO May 2017.

 
Link  NICE TA536: Alectinib for untreated ALK-positive advanced non-small-cell lung cancer
   
Avelumab (Bavencio®)
View adult BNF View SPC online View childrens BNF
Formulary
Red
High Cost Medicine
NHS England

For treating metastatic Merkel cell carcinoma, as per NICE TA517. 

Funded by specialised commissioning. 

APCO May 2018. 

 
Link  NICE TA517: Avelumab for treating metastatic Merkel cell carcinoma
   
Axitinib (Inlyta®)
View adult BNF View SPC online View childrens BNF
Formulary
Red
High Cost Medicine

For treating advanced renal cell carcinoma after failure of prior systemic treatment as per NICE TA333.

Funded by specialised commissioning.

APCO March 2015.

 
Link  NICE TA333: Axitinib for advanced renal cell carcinoma
   
Bevacizumab (Avastin®)
View adult BNF View SPC online View childrens BNF
Restricted Drug Restricted
Cancer Drugs Fund

Red Traffic Light  For ovarian cancer (as per Bevacizumab Extended Access Program) and neurofibromatosis type 2 (off-label use).

Black Traffic Light

    • First-line for the treatment of advanced and/or metastatic renal cell carcinoma as per NICE TA178.
    • Diabetic macular oedema (APCO January 2012).
    • Macular oedema caused by retinal vein occlusion (APCO January 2012).
    • Metastatic colorectal cancer after first line chemotherapy as per NICE TA242.
    • First-line treatment of metastatic breast cancer as per NICE TA214.
    • In combination with capecitabine. First line treatment of metastatic breast cancer as per NICE TA263.
    • In combination with gemcitabine and carboplatin for first recurrence of platinum-sensitive advanced ovarian cancer as per NICE TA285.
    • In combination with oxaliplatin and either fluorouracil plus folinic acid or capecitabine for treatment of metastatic colorectal cancer as per NICE TA212.
    • In combination with paclitaxel and carboplatin for first-line treatment of advanced ovarian cancer as per NICE TA284.
    • Bevacizumab for treating relapsed, platinum‑resistant epithelial ovarian, fallopian tube or primary peritoneal cancer (NICE TA353 - terminated appraisal).
    • Bevacizumab for treating EGFR mutation-positive non-small-cell lung cancer (NICE TA436 - terminated appraisal). APCO May 2017. 

 

 
Link  NICE TA178: Bevacizumab (first-line), sorafenib (first- and second-line), sunitinib (second-line) and temsirolimus (first-line) for the treatment of advanced and/or metastatic renal cell carcinoma
Link  NICE TA212: Bevacizumab in combination with oxaliplatin and either fluorouracil plus folinic acid or capecitabine for the treatment of metastatic colorectal cancer
Link  NICE TA214: Bevacizumab in combination with a taxane for the first-line treatment of metastatic breast cancer
Link  NICE TA242: Cetuximab, bevacizumab and panitumumab for the treatment of metastatic colorectal cancer after first-line chemotherapy: Cetuximab (monotherapy or combination chemotherapy), bevacizumab (in combination with non-oxaliplatin chemotherapy) and pan
Link  NICE TA263: Bevacizumab in combination with capecitabine for the first-line treatment of metastatic breast cancer
Link  NICE TA284: Bevacizumab in combination with paclitaxel and carboplatin for first-line treatment of advanced ovarian cancer
Link  NICE TA285: Bevacizumab in combination with gemcitabine and carboplatin for treating the first recurrence of platinum-sensitive advanced ovarian cancer
   
Bosutinib (Bosulif®)
View adult BNF View SPC online View childrens BNF
Formulary
Red
Cancer Drugs Fund

For previously treated chronic myeloid leukaemia as per NICE TA401.

APCO September 2016.

Black Traffic Light Not recommended for untreated chronic myeloid leukaemia as per NICE TA576 (terminated appraisal).

APCO May 2019.

 
Link  NICE TA401: Bosutinib for previously treated chronic myeloid leukaemia
Link  NICE TA576: Bosutinib for untreated chronic myeloid leukaemia (terminated appraisal)
   
Carfilzomib (Kyprolis®)
View adult BNF View SPC online View childrens BNF
Formulary
Red

For previously treated multiple myeloma as per NICE TA457.

Funded by specialised commissioning.

APCO September 2017.

 
Link  NICE TA457: Carfilzomib for previously treated multiple myeloma
   
Ceritinib (Zykadia®)
View adult BNF View SPC online View childrens BNF
Formulary
Red
Cancer Drugs Fund
NHS England

For:

  • Previously treated anaplastic lymphoma kinase positive non-small-cell lung cancer as per NICE TA395 (APCO July 2016).
  • Untreated anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer in adults as per NICE TA500 (APCO March 2018).
 
Link  NICE TA395: Ceritinib for previously treated anaplastic lymphoma kinase positive non-small-cell lung cancer
Link  NICE TA500: Ceritinib for untreated ALK-positive non-small-cell lung cancer
   
Dabrafenib (Tafinlar®)
View adult BNF View SPC online View childrens BNF
Formulary
High Cost Medicine
Cancer Drugs Fund
NHS England

Red 

  • In combination with trametinib for treating unresectable or metastatic melanoma as per NICE TA396 (APCO July 2016).
  • In combination with trametinib for adjuvant treatment of resected BRAF V600 mutation-positive melanoma as per NICE TA544 (APCO November 2018).

Funded by specialised commissioning.

 Black Traffic Light Not recommended for treating advanced metastatic BRAF V600E mutation-positive non-small-cell lung cancer in combination with trametinib as per NICE TA564 (terminated appraisal).

APCO March 2019.

 
Link  NICE TA321:Dabrafenib for BRAF V600 +ve melanoma
Link  NICE TA396:Trametinib in combination with dabrafenib for treating unresectable or metastatic melanoma
Link  NICE TA544: Dabrafenib with trametinib for adjuvant treatment of resected BRAF V600 mutation-positive melanoma
Link  NICE TA564: Dabrafenib with trametinib for treating advanced metastatic BRAF V600E mutation-positive non-small-cell lung cancer (terminated appraisal)
   
Cytotoxic Drug Daratumumab (Darzalex®)
View adult BNF View SPC online View childrens BNF
Formulary
High Cost Medicine
NHS England

Red Traffic Light  

  • Monotherapy for treating relapsed and refractory multiple myeloma as per NICE TA510 (APCO May 2018). 
  • With bortezomib and dexamethasone for previously treated multiple myeloma as per NICE TA573 (APCO May 2019).

Funded by specialised commissioning.

Black Traffic Light Not recommended for treating relapsed or refractory multiple myeloma with lenalidomide and dexamethasone.

APCO September 2017.

 
Link  NICE TA510: Daratumumab monotherapy for treating relapsed and refractory multiple myeloma
Link  NICE TA573: Daratumumab with bortezomib and dexamethasone for previously treated multiple myeloma
   
Cytotoxic Drug Eribulin (Halaven®)
View adult BNF View SPC online View childrens BNF
Formulary
High Cost Medicine
Cancer Drugs Fund

Red Traffic Light  For treating locally advanced or metastatic breast cancer after 2 or more chemotherapy regimens as per NICE TA423.

APCO January 2017.

Black Traffic Light  Not recommended for treating locally advanced or metastatic breast cancer after 1 year chemotherapy regimen as per NICE TA515. 

APCO May 2018. 

 
Link  NICE TA423: Eribulin for treating locally advanced or metastatic breast cancer after 2 or more chemotherapy regimens
Link  NICE TA515: Eribulin for treating locally advanced or metastatic breast cancer after 1 chemotherapy regimen
Link  SMC advice (March 2016)
   
Ibrutinib (Imbruvica®)
View adult BNF View SPC online View childrens BNF
Formulary
High Cost Medicine
Cancer Drugs Fund
NHS England

Red Traffic Light  For treating;

  • Previously treated chronic lymphocytic leukaemia and untreated chronic lymphocytic leukaemia with 17p deletion or TP53 mutation as per NICE TA429 (APCO March 2017).
  • Waldenstrom's macroglobulinaemia as per NICE TA491 (APCO January 2018).
  • Relapsed or refractory mantle cell lymphoma in adults as per NICE TA502 (APCO March 2018).

Black Traffic Light  For:

    • Relapsed or refractory chronic lymphocytic leukaemia after systemic therapy (with bendamustine and rituximab) NICE TA437 - terminated appraisal (APCO May 2017).
    • Untreated chronic lymphocytic leukaemia without a 17p deletion or TP53 mutation as per NICE TA465 - terminated appraisal (APCO September 2017).
    • With rituximab for treating Waldenstrom’s macroglobulinaemia as per NICE TA608 - terminated appraisal (APCO January 2020).
 
Link  NICE TA429: Ibrutinib for previously treated chronic lymphocytic leukaemia and untreated chronic lymphocytic leukaemia with 17p deletion or TP53 mutation
Link  NICE TA491: Ibrutinib for treating Waldenstrom’s macroglobulinaemia
Link  NICE TA608: Ibrutinib with rituximab for treating Waldenstrom’s macroglobulinaemia (terminated appraisal)
Link  MHRA: Reports of ventricular tachyarrhythmia; risk of hepatitis B reactivation and of opportunistic infections
   
Idelalisib (Zydelig®)
View adult BNF View SPC online View childrens BNF
Formulary

Red Traffic Light  For treating chronic lymphocytic leukaemia as per NICE TA359.

APCO November 2015.

Black Traffic Light  Not recommended for

  • For treating chronic lymphocytic leukaemia with ofatumumab as per NICE TA469 - terminated appraisal (APCO September 2017).
  • For treating refractory follicular lymphoma as per NICE TA604 (APCO November 2019).
 
Link  NICE TA359: Chronic lymphocytic leukaemia - Idelalisib
Link  NICE TA604: Idelalisib for treating refractory follicular lymphoma
Link  MHRA: Interim advice in light of new findings related to infection
   
Inotuzumab ozogamicin (Besponsa®)
View adult BNF View SPC online View childrens BNF
Formulary
Red
NHS England

For treating relapsed or refractory B-cell acute lymphoblastic leukaemia as per NICE TA541.

Funded by specialised commissioning.

APCO November 2018.

 
Link  NICE TA541: Inotuzumab ozogamicin for treating relapsed or refractory B-cell acute lymphoblastic leukaemia
   
Ixazomib (Ninlaro®)
View adult BNF View SPC online View childrens BNF
Formulary
Red
NHS England

With lenalidomide and dexamethasone for relapsed or refractory multiple myeloma in adults as per NICE TA505.

 
Link  NICE TA505: Ixazomib with lenalidomide and dexamethasone for treating relapsed or refractory multiple myeloma
   
Lenvatinib (Lenvima®)
View adult BNF View SPC online View childrens BNF
Formulary
Red
NHS England
  • For treating differentiated thyroid cancer after radioactive iodine as per NICE TA535 (APCO September 2018).
  • for untreated advanced hepatocellular carcinoma as per NICE TA551 (APCO March 2019).

Funded by specialised commissioning. 

 

 
Link  NICE TA535: Lenvatinib and sorafenib for treating differentiated thyroid cancer after radioactive iodine
Link  NICE TA551:Lenvatinib for untreated advanced hepatocellular carcinoma
   
Niraparib (Zejula®)
View adult BNF View SPC online View childrens BNF
Formulary
Red
NHS England
  • For treating ovarian/fallopian tube/peritoneal cancer (APCO September 2017).
  • For maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer, as per NICE TA528. Funded by specialised commissioning. (APCO September 2018).
 
Link  NICE TA528: Niraparib for maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer
   
Cytotoxic Drug Olaratumab (Lartruvo®)
View adult BNF View SPC online View childrens BNF
Formulary
Red
Cancer Drugs Fund

In combination with doxorubicin for treating advanced soft tissue sarcoma as per NICE TA465

APCO September 2017.

 
   
Cytotoxic Drug Panitumumab (Vectibix®)
View adult BNF View SPC online View childrens BNF
Formulary
High Cost Medicine
Cancer Drugs Fund

Red Traffic Light  For the treatment of previously untreated metastatic colorectal cancer in combination with cetuximab as per NICE TA439 (APCO May 2017).

Funded by specialised commissioning.

Black Traffic Light  For the treatment of:

  • Metastatic colorectal cancer after first-line chemotherapy as per NICE TA242 (APCO March 2012).
  • Metastatic colorectal cancer in combination with chemotherapy (NICE TA240 -terminated appraisal). APCO May 2017.


 
Link  NICE TA439: Cetuximab and panitumumab for previously untreated metastatic colorectal cancer
   
Pembrolizumab (Keytruda®)
View adult BNF View SPC online View childrens BNF
Formulary
High Cost Medicine
NHS England

Red Traffic Light For the treatment of:

    • Advanced melanoma after disease progression with ipilimumabas per NICE TA357 (APCO November 2015).
    • Advanced melanoma not previously treated with ipilimumab as per NICE TA366 (APCO January 2016).
    • PD-L1-positive non-small-cell lung cancer after chemotherapy as per NICE TA428 (APCO March 2017).
    • Locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy as per NICE TA519 (APCO May 2018).
    • Untreated PD-L1-positive locally advanced or metastatic urothelial cancer when cisplatin is unsuitable as per NICE TA522 (APCO September 2018). 
    • Untreated PD-L1-positive metastatic non-small-cell lung cancer as per NICE TA531 (APCO September 2018).
    • Relapsed or refractory classical Hodgkin lymphoma (for patients who cannot have an autologous stem cell transplant) as per NICE TA 540 (APCO November 2018).
    • Adjuvant treatment of resected melanoma with high risk of recurrence as per NICE TA553 (APCO March 2019).
    • Pembrolizumab with pemetrexed and platinum chemotherapy for untreated, metastatic, non-squamous non-small-cell lung cancer as per NICE TA557 (APCO March 2019). 
    • Pembrolizumab with carboplatin and paclitaxel for untreated metastatic squamous non-small-cell lung cancer as per NICE TA600 (APCO November 2019).

Funded by specialised commissioning.

Black Traffic Light Not recommended:

  • For treating relapsed or refractory classical Hodgkin lymphoma for patients who have had autologous stem cell transplant as per NICE TA540 (APCO November 2018).
  • For treating recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy as per NICE TA570 (terminated appraisal)  (APCO May 2019). 

 

 
Link  NICE TA357: Pembrolizumab for melanoma after ipilimumab
Link  NICE TA366: Pembrolizumab for advanced melanoma not previously treated with ipilimumab
Link  NICE TA428: Pembrolizumab for treating PD-L1-positive non-small-cell lung cancer after chemotherapy
Link  NICE TA519: Pembrolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy
Link  NICE TA522: Pembrolizumab for untreated PD-L1-positive locally advanced or metastatic urothelial cancer when cisplatin is unsuitable
Link  NICE TA531: Pembrolizumab for untreated PD-L1-positive metastatic non-small-cell lung cancer
Link  NICE TA540: Pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma
Link  NICE TA553: Pembrolizumab for adjuvant treatment of resected melanoma with high risk of recurrence
Link  NICE TA557: Pembrolizumab with pemetrexed and platinum chemotherapy for untreated, metastatic, non-squamous non-small-cell lung cancer
Link  NICE TA570: Pembrolizumab for treating recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy (terminated appraisal)
Link  NICE TA600: Pembrolizumab with carboplatin and paclitaxel for untreated metastatic squamous non-small-cell lung cancer
   
Ponatinib (Iclusig®)
View adult BNF View SPC online View childrens BNF
Formulary
Red
High Cost Medicine
Cancer Drugs Fund

For treating chronic myeloid leukaemia and acute lymphoblastic leukaemia in adults as per NICE TA451.

Funded by specialised commissioning.

APCO November 2017.

 
Link  MHRA: Risk of vascular occlusive events with ponatinib
Link  NICE TA451: Ponatinib for treating chronic myeloid leukaemia and acute lymphoblastic leukaemia
   
Ruxolitinib (Jakavi®)
View adult BNF View SPC online View childrens BNF
Formulary
Red
High Cost Medicine

For the treatment of disease-related splenomegaly or symptoms in adults with myelofifibrosis (also known as chronic idiopathic myelofibrosis), post polycythaemia vera myelofibrosis or post essential thrombocythaemia myelofibrosis as per NICE TA386.

Funded by specialised commissioning.

APCO May 2016.

 
Link  NICE TA386: Ruxolitinib for treating disease-related splenomegaly or symptoms in adults with myelofibrosis
   
Cytotoxic Drug Talimogene laherparepvec (Imlygic®)
View adult BNF View SPC online View childrens BNF
Formulary
Red

For treating unresectable metastatic melanoma as per NICE TA410.

APCO November 2016.

 
Link  NICE TA410: Talimogene laherparepvec for treating unresectable metastatic melanoma
   
Trametinib (Mekinist®)
View adult BNF View SPC online View childrens BNF
Formulary
Red
High Cost Medicine
Cancer Drugs Fund

In combination with dabrafenib for treating unresectable or metastatic melanoma as per NICE TA396.

APCO July 2016.

 
Link  NICE TA396: Trametinib in combination with dabrafenib for treating unresectable or metastatic melanoma
Link  MHRA: Risk of gastrointestinal perforation and colitis
   
Venetoclax (Venclyxto®)
View adult BNF View SPC online View childrens BNF
Formulary
Red
Cancer Drugs Fund
  • For treating chronic lymphocytic leukaemia as per NICE TA487 (APCO January 2018).
  • For previously treated chronic lymphocytic leukaemia in combination with Rituximab as per NICE TA561 (APCO March 2019).

Funded by specialised commissioning.

 
Link  NICE TA487: Venetoclax for treating chronic lymphocytic leukaemia
Link  NICE TA561: Venetoclax with rituximab for previously treated chronic lymphocytic leukaemia
   
08.01.05  Expand sub section  Amsacrine
08.01.05  Expand sub section  Arsenic trioxide
Cytotoxic Drug Arsenic Trioxide (Trisenox®)
View adult BNF View SPC online View childrens BNF
Formulary
Red
NHS England

For treating acute promyelocytic leukaemia as per NICE TA526.

APCO July 2018.

 
Link  NICE TA526: Arsenic trioxide for treating acute promyelocytic leukaemia
   
08.01.05  Expand sub section  Bexarotene
08.01.05  Expand sub section  Bortezomib to top
Cytotoxic Drug Bortezomib (Velcade®)
View adult BNF View SPC online View childrens BNF
Formulary
High Cost Medicine
Cancer Drugs Fund

Red Traffic Light  For the treatment of:

  • Multiple Myeloma as per NICE TA129, TA228 and TA311 (APCO September 2011).
  • Mantel cell lymphoma as per NICE TA370 (APCO January 2016).

Black Traffic Light  For treating multiple myeloma after second or subsequent relapse NICE TA453 (terminated appraisal).

APCO September 2017.

 
Link  NICE TA129: Multiple myeloma - bortezomib
Link  NICE TA228: 1st line treatment of multiple myeloma
Link  NICE TA311: Bortezomib for induction therapy in multiple myeloma
Link  NICE TA370: Bortezomib for previously untreated mantle cell lymphoma
Link  MHRA: Risk of cracked or broken vials
   
08.01.05  Expand sub section  Brentuximab vedotin
Brentuximab vedotin (Adcetris®)
View adult BNF View SPC online View childrens BNF
Formulary
High Cost Medicine
Cancer Drugs Fund
NHS England

Red Traffic Light For the treatment of:

  • Relapsed or refractory systemic anaplastic large cell lymphoma as per NICE TA478 (APCO November 2017).
  • CD30-positive Hodgkin lymphoma as per NICE TA524 (APCO July 2018). 
  • CD30-positive cutaneous T-cell lymphoma in line with NICE TA577 (APCO July 2019).

Funded by specialised commissioning.

Black Traffic Light Not recommended for untreated advanced Hodgkin lymphoma in line with NICE TA594 (terminated appraisal).

APCO September 2019.

 
Link  Brentuximab vedotin for treating CD30-positive cutaneous T-cell lymphoma
Link  NICE TA478: Brentuximab vedotin for treating relapsed or refractory systemic anaplastic large cell lymphoma
Link  NICE TA524: Brentuximab vedotin for treating CD30-positive Hodgkin lymphoma
Link  NICE TA594: Brentuximab vedotin for untreated advanced Hodgkin lymphoma (terminated appraisal)
   
08.01.05  Expand sub section  Cetuximab
Cetuximab (Erbitux®)
View adult BNF View SPC online View childrens BNF
Formulary
High Cost Medicine
Cancer Drugs Fund

Red Traffic Light  For the treatment of:

  • Locally advanced squamous cell cancer of the head and neck as per NICE TA145.
  • Previously untreated metastatic colorectal cancer in combination with panitumumab as per NICE TA439 (APCO May 2017). 
  • Recurrent or metastatic squamous cell cancer of the head and neck as per NICE TA473 (APCO November 2017).

Funded by specialised commissioning. 

Black Traffic Light  For the treatment of:

  • Recurrent or metastatic squamous cell cancer of the head and neck as per NICE TA172 (APCO July 2009).
  • Metastatic colorectal cancer after first-line chemotherapy as per NICE TA242 (APCO March 2012).
 
Link  NICE TA145: Head and neck cancer - cetuximab
Link  NICE TA172: Recurrent and/or metastatic squamous cell cancer of the head and neck
Link  NICE TA242: Metastatic colorectal cancer after first-line chemotherapy
Link  NICE TA439: Cetuximab and panitumumab for previously untreated metastatic colorectal cancer
Link  NICE TA473: Cetuximab for treating recurrent or metastatic squamous cell cancer of the head and neck
Link  MHRA: importance of establishing wild type RAS (KRAS and NRAS) status before treatment of metastatic colorectal cancer
   
08.01.05  Expand sub section  Crisantaspase
Crisantaspase (Erwinase®)
View adult BNF View SPC online View childrens BNF
Formulary
Red

For patients being treated on the UKALL 2011 (Paediatric Haemato-oncology).

 

 
   
08.01.05  Expand sub section  Dacarbazine and Temozolomide
Cytotoxic Drug Dacarbazine
View adult BNF View SPC online View childrens BNF
Formulary
Red

Secondary care use only. 

 
   
Cytotoxic Drug Temozolomide (Temodal®)
View adult BNF View SPC online View childrens BNF
Formulary
Red
High Cost Medicine

For the treatment of;

  • Recurrent malignant glioma (brain cancer) as per NICE TA23.
  • Newly diagnosed high-grade glioma as per NICE TA121.


APCO May 2011.

 
Link  NICE TA121: Glioma (newly diagnosed and high grade)
Link  NICE TA23: Guidance on the use of temozolomide for the treatment of recurrent malignant glioma (brain cancer)
Link  MHRA: Risk of hepatic injury, including fatal hepatic failure
   
08.01.05  Expand sub section  Erlotinib to top
Erlotinib (Tarceva® )
View adult BNF View SPC online View childrens BNF
Formulary
High Cost Medicine

Red Traffic Light  For the treatment of:

  • Non-small-cell lung cancer that has progressed after prior chemotherapy if EGFR-TK POSITIVE (or likely to be) as per NICE TA374 (APCO January 2016).
  • First-line treatment of locally advanced or metastatic EGFR-TK mutation-positive non-small-cell lung cancer as per NICE TA258 (APCO September 2012).


Black Traffic Light  For the treatment of:

  • Non-small-cell lung cancer that has progressed after prior chemotherapy if EGFR-TK NEGATIVE (or likely to be) as per NICE TA374 (APCO January 2016).
  • Monotherapy for maintenance treatment of non-small-cell lung cancer as per NICE TA227 (APCO September 2011).

 
Link  NICE TA227: Lung cancer (non-small-cell) maintenance - erlotinib
Link  NICE TA258: Lung cancer (non-small-cell) 1st line- erlotinib
Link  NICE TA374: Erlotinib and gefitinib for treating non-small-cell lung cancer that has progressed after prior chemotherapy
   
08.01.05  Expand sub section  Hydroxycarbamide
Hydroxycarbamide (500mg/5ml oral liquid)
View adult BNF View SPC online View childrens BNF
Formulary
Red

Secondary care use only. Liquid formulation is not included in the shared care protocols. 

APCO November 2019.

 
   
Cytotoxic Drug Hydroxycarbamide (Hydroxyurea) (Hydrea®)
(Tablets/ capsules)
View adult BNF View SPC online View childrens BNF
Formulary
Amber Shared Care Protocol

 

 

 
   
08.01.05  Expand sub section  Imatinab
08.01.05  Expand sub section  Ipilimumab
Ipilimumab (Yervoy®)
View adult BNF View SPC online View childrens BNF
Formulary
Red
High Cost Medicine
Cancer Drugs Fund

For previously untreated advanced (unresectable or metastatic) melanoma  as per NICE TA319.

 
Link  NICE TA268: Ipilimumab for previously treated advanced (unresectable or metastatic) melanoma
Link  NICE TA319: Ipilimumab for previously untreated advanced (unresectable or metastatic) melanoma
Link  NICE TA400: Nivolumab in combination with ipilimumab for treating advanced melanoma
   
08.01.05  Expand sub section  Mitotane
Mitotane (Lysodren®)
View adult BNF View SPC online View childrens BNF
Formulary
Red

Secondary care use only. 

APCO July 2008.

 
   
08.01.05  Expand sub section  Panitumumab to top
08.01.05  Expand sub section  Pentostatin
Cytotoxic Drug Pentostatin (Nipent®)
View adult BNF View SPC online View childrens BNF
Formulary
Red

Secondary care use only. 

 
   
08.01.05  Expand sub section  Platinum compounds
Cytotoxic Drug Oxaliplatin
View adult BNF View SPC online View childrens BNF
Formulary
Red

In combination with capecitabine in the adjuvant treatment of stage III (Dukes' C) colon cancer as per NICE TA100.

 
Link  NICE TA100: Colon cancer (adjuvant) - capecitabine and oxaliplatin
   
08.01.05  Expand sub section  Porfimer sodium and temoporfin
08.01.05  Expand sub section  Procarbazine
Cytotoxic Drug Procarbazine
View adult BNF View SPC online View childrens BNF
Formulary
Red

Secondary care use only. 

APCO July 2008.

 
   
08.01.05  Expand sub section  Protein kinase inhibitors to top
Abemaciclib (Verzenios®)
View adult BNF View SPC online View childrens BNF
Formulary
Red
  • For previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer in combination with an aromatase inhibitor, as per NICE TA563 (APCO March 2019).
  • With fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy as per NICE TA579 (APCO July 2019). Funded by specialised commissioning. 
 
Link  NICE TA563: Abemaciclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer
Link  NICE TA579: Abemaciclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy
   
Afatinib (Giotrif®)
View adult BNF View SPC online View childrens BNF
Formulary
NHS England

Red Traffic Light  For treating epidermal growth factor receptor mutation-positive locally advanced or metastatic non-small-cell lung cancer as per NICE TA310.

Funded by specialised commissioning.

APCO May 2014.

Black Traffic Light  For treating advanced squamous non-small-cell lung cancer after platinum-based chemotherapy (Terminated appraisal NICE TA444).

APCO July 2017. 

 
Link  NICE TA310: Afatinib for treating epidermal growth factor receptor mutation-positive locally advanced or metastatic non-small-cell lung cancer
Link  NICE TA444: Afatinib for treating advanced squamous non-small-cell lung cancer after platinum-based chemotherapy (terminated appraisal)
   
Brigatinib (Alunbrig®)
View adult BNF View SPC online View childrens BNF
Formulary
Red
NHS England

For treating ALK-positive advanced non-small-cell lung cancer after crizotinib as per NICE TA571.

Funded by specialised commissioning.

APCO May 2019.

 
Link  NICE TA571: Brigatinib for treating ALK-positive advanced non-small-cell lung cancer after crizotinib
   
Cabozantinib (Cabometyx®)
View adult BNF View SPC online View childrens BNF
Formulary
Red
High Cost Medicine
NHS England

For treating

  • Previously treated advanced renal cell carcinoma as per NICE TA463 (APCO September 2017).
  • Untreated advanced renal cell carcinoma as per NICE TA542 (APCO November 2018).

Funded by specialised commissioning.

 

 
Link  NICE TA463: Cabozantinib for previously treated advanced renal cell carcinoma
Link  NICE TA542: Cabozantinib for untreated advanced renal cell carcinoma
   
Cabozantinib (Cometriq®)
View adult BNF View SPC online View childrens BNF
Formulary
Cancer Drugs Fund
NHS England

Red Traffic Light For treating medullary thyroid cancer, as per NICE TA516.

Funded by specialised commissioning.

APCO May 2018. 

Black Traffic Light Not recommended for previously treated advanced hepatocellular carcinoma as per NICE TA582 (terminated appraisal). 

APCO July 2019.

 
Link  NICE TA516: Cabozantinib for treating medullary thyroid cancer
Link  NICE TA582: Cabozantinib for previously treated advanced hepatocellular carcinoma (terminated appraisal)
   
Crizotinib (Xalkori®)
View adult BNF View SPC online View childrens BNF
Formulary
Red
High Cost Medicine
Cancer Drugs Fund

For:

  • Untreated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer as per NICE TA406 (APCO November 2016).
  • Previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer as per NICE TA422 (APCO January 2017).
  • For treating ROS1-positive advanced non-small-cell lung cancer as per NICE TA529 (APCO September 2018). 

Funded by specialised commissioning.

 
Link  NICE TA406: Crizotinib for untreated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer
Link  NICE TA422: Crizotinib for previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer
Link  NICE TA529: Crizotinib for treating ROS1-positive advanced non-small-cell lung cancer
Link  MHRA: Risk of cardiac failure with crizotinib
   
Dacomitinib  (Vizimpro®)
View adult BNF View SPC online View childrens BNF
Formulary
Red

For untreated EGFR mutation-positive non-small-cell lung cancer as per NICE TA595.

Funded by specialised commissioning. 

APCO September 2019.

 
Link  NICE TA595: Dacomitinib for untreated EGFR mutation-positive non-small-cell lung cancer
   
Dasatinib (Sprycel®)
View adult BNF View SPC online View childrens BNF
Formulary
High Cost Medicine
Cancer Drugs Fund

Red Traffic Light  For the treatment of:

  • Imatinib-resistant or intolerant chronic myeloid leukaemia as per NICE TA425.
  • Untreated chronic myeloid leukaemia as per NICE TA426.

Funded by specialised commissioning.

APCO January 2017.

Black Traffic Light  Not recommended for patients with CML resistant to standard dose imatinib or unable to tolerate imatinib as per NICE TA241.

APCO March 2012.

 
Link  NICE TA241: CML where treatment with imatinib has failed
Link  NICE TA425: Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia
   
Encorafenib (Braftovi®)
View adult BNF View SPC online View childrens BNF
Formulary
Red

For treating unresectable or metastatic BRAF V600 mutation-positive melanoma in combination with binimetinib as per NICE TA562.

Funded by specialised commissioning.

APCO March 2019.

 

 
Link  NICE TA562: Encorafenib with binimetinib for unresectable or metastatic BRAF V600 mutation-positive melanoma
   
Cytotoxic Drug Everolimus
View adult BNF View SPC online View childrens BNF
Formulary
High Cost Medicine
Cancer Drugs Fund

Red Traffic Light  For:

  • Treating advanced breast cancer in combination with exemestane after endocrine therapy as per NICE TA421 (APCO January 2017).
  • Treating advanced renal cell carcinoma after previous treatment as per NICE TA432 (APCO March 2017).
  • Use with sunitinib for treating unresectable or metastatic neuroendocrine tumours in people with progressive disease as per NICE TA449 (APCO July 2017). 
  • SEGA-TS, agreed at MMTC in October 2018 (APCO November 2018).

Funded by specialised commissioning.

Black Traffic Light  Not recommended for renal transplant patients as per NICE TA481 and TA482.

APCO November 2017.

 
Link  NICE TA421: Everolimus with exemestane for treating advanced breast cancer after endocrine therapy
Link  NICE TA432: Everolimus for advanced renal cell carcinoma after previous treatment
Link  NICE TA449: Everolimus and sunitinib for treating unresectable or metastatic neuroendocrine tumours in people with progressive disease
Link  NICE TA481: Immunosuppressive therapy for kidney transplant in adults
Link  NICE TA482: Immunosuppressive therapy for kidney transplant in children and young people
   
Gefitinib (Iressa®)
View adult BNF View SPC online View childrens BNF
Formulary
High Cost Medicine

Red Traffic Light  For the first-line treatment of locally advanced or metastatic non-small-cell lung cancer as per NICE TA192.

Funded by specialised commissioning.

APCO September 2010.

Black Traffic Light  Not recommended for treating non-small-cell lung cancer that has progressed after prior chemotherapy as per NICE TA374.

APCO January 2016.

 
Link  NICE TA192: Lung cancer (non-small-cell, first line) - gefitinib
Link  NICE TA374: Erlotinib and gefitinib for treating non-small-cell lung cancer that has progressed after prior chemotherapy
   
Cytotoxic Drug Imatinib (Gilvec®)
(100mg and 400mg )
View adult BNF View SPC online View childrens BNF
Formulary
Red
High Cost Medicine
Cancer Drugs Fund

For the treatment of:

  • Gastrointestinal stromal tumours as per NICE TA86 and NICE TA326 (APCO January 2015).
  • Untreated chronic myeloid leukaemia as per NICE TA70 and NICE TA426 (APCO January 2017).
  • Chronic graft versus host disease as per NHS England: 16069/P (APCO September 2017).

Funded by specialised commissioning.

 
Link  NICE TA70: Guidance on the use of imatinib for chronic myeloid leukaemia
Link  NICE TA86: Imatinib for the treatment of unresectable and/or metastatic gastro-intestinal stromal tumours
Link  NICE TA326: Imatinib for the adjuvant treatment of gastrointestinal stromal tumours
Link  NICE TA426: Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia
   
Lenvatinib (Kisplyx®)
View adult BNF View SPC online View childrens BNF
Formulary
Red
NHS England

With everolimus for previously treated advanced renal cell carcinoma in adults as per NICE TA498.

APCO March 2018.

 
Link  NICE TA498: Lenvatinib with everolimus for previously treated advanced renal cell carcinoma
   
Midostaurin (Rydapt®)
View adult BNF View SPC online View childrens BNF
Formulary
Red
NHS England

Red Traffic Light  For untreated acute myeloid leukaemia as per NICE TA523.

Funded by specialised commissioning.

APCO July 2018.

 
Link  NICE TA523: Midostaurin for untreated acute myeloid leukaemia
   
Nilotinib (Tasigna®)
View adult BNF View SPC online View childrens BNF
Formulary
Red
High Cost Medicine

For the treatment of:

  • Imatinib-resistant or intolerant chronic myeloid leukaemia as per NICE TA425.
  • Untreated chronic myeloid leukaemia as per NICE TA426.

Funded by specialised commissioning.

APCO January 2017.

 
Link  NICE TA241: Dasatinib, nilotinib and high dose imatinib for CML
Link  NICE TA251: Dasatinib, nilotinib and imatinib for first line treatment of CML
   
Nintedanib  (Vargatef®)
View adult BNF View SPC online View childrens BNF
Formulary
Red
High Cost Medicine

For previously treated locally advanced, metastatic, or locally recurrent non‑small‑cell lung cancer as per NICE TA347.

Funded by specialised commissioning.

APCO September 2015.

 
   
Palbociclib (Ibrance®)
View adult BNF View SPC online View childrens BNF
Formulary
Red

With an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer as per NICE TA495.

Funded by specialised commissioning.

APCO January 2018.

 
Link  NICE TA495: Palbociclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer
   
Pazopanib (Votrient®)
View adult BNF View SPC online View childrens BNF
Formulary
Red
High Cost Medicine
NHS England

For first-line treatment of advanced renal cell carcinoma as per NICE TA215.

Funded by specialised commissioning.

APCO May 2011.

 
Link  NICE TA215: Pazopanib in renal cell cancer
   
Regorafenib (Stivarga® )
View adult BNF View SPC online View childrens BNF
Formulary
High Cost Medicine
Cancer Drugs Fund
NHS England

Red Traffic Light 

  • For previously treated unresectable or metastatic gastrointestinal stromal tumours as per NICE TA488 (APCO January 2018).
  • For previously treated advanced hepatocellular carcinoma as per NICE TA555 (APCO March 2019).

Funded by specialised commissioning.

Black Traffic Light Not recommended for previously treated advanced hepatocellular carcinoma as per NICE TA514. 

APCO May 2018.

 
Link  NICE TA488: Regorafenib for previously treated unresectable or metastatic gastrointestinal stromal tumours
Link  NICE TA514: Regorafenib for previously treated advanced hepatocellular carcinoma
Link  NICE TA555: Regorafenib for previously treated advanced hepatocellular carcinoma
   
Ribociclib (Kisqali®)
View adult BNF View SPC online View childrens BNF
Formulary
Red

With an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer as per NICE TA496.

Funded by specialised commissioning.

APCO January 2018.

 
Link  NICE TA496: Ribociclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer
   
Sorafenib (Nexavar®)
View adult BNF View SPC online View childrens BNF
Formulary
High Cost Medicine
Cancer Drugs Fund
NHS England

Red Traffic Light For the treatment of:

  • Advanced hepatocellular carcinoma as per NICE TA474 (APCO November 2017).
  • Differentiated thyroid cancer after radioactive iodine as per NICE TA535 (APCO September 2018).

Funded by specialised commissioning.

Black Traffic Light   Not recommended for:

  • Treatment of advanced hepatocellular carcinoma as per NICE TA189 (APCO July 2010).
  • Treatment of advanced or metastatic renal cell carcinoma (first- and second-line) as per NICE TA178 (APCO September 2009).
 
Link  NICE TA474: Sorafenib for treating advanced hepatocellular carcinoma
Link  NICE TA535: Lenvatinib and sorafenib for treating differentiated thyroid cancer after radioactive iodine
   
Sunitinib (Sutent®)
View adult BNF View SPC online View childrens BNF
Formulary
Red
High Cost Medicine
Cancer Drugs Fund

For the treatment of:

  • Advanced and/or metastatic renal cell carcinoma as per NICE TA169 (APCO July 2009).
  • Gastrointestinal stromal tumours as per NICE TA179 (APCO November 2009).
  • With everolimus for treating unresectable or metastatic neuroendocrine tumours in people with progressive disease ss per NICE TA449 (APCO July 2017). Funded by specialised commissioning. 

 
Link  NICE TA169: Renal cell carcinoma - sunitinib
Link  NICE TA179: Gastrointestinal stromal tumours - sunitinib
Link  NICE TA449: Everolimus and sunitinib for treating unresectable or metastatic neuroendocrine tumours in people with progressive disease
Link  MHRA: Risk of osteonecrosis of the jaw
   
Tivozanib (Fotivda®)
View adult BNF View SPC online View childrens BNF
Formulary
Red
High Cost Medicine
NHS England

For treating advanced renal cell carcinoma, in line with NICE TA512. 

Funded by specialised commissioning. 

APCO May 2018. 

 
Link  NICE TA512: Tivozanib for treating advanced renal cell carcinoma
   
Vemurafenib (Zelboraf®)
View adult BNF View SPC online View childrens BNF
Formulary
Red
High Cost Medicine
NHS England

For unresectable or metastatic melanoma with the BRAF V600 mutation as per NICE TA269.

Funded by specialised commissioning.

APCO January 2013.

 
Link  NICE TA269: Vemurafenib for treating malignant melanoma
Link  MHRA: Risk of potentiation of radiation toxicity with vemurafenib
   
08.01.05  Expand sub section  Taxanes
Cytotoxic Drug Cabazitaxel (Jevtana®)
View adult BNF View SPC online View childrens BNF
Formulary
Red
High Cost Medicine
Cancer Drugs Fund

For hormone-refractory metastatic prostate cancer previously treated with a docetaxel as per NICE TA391.

APCO July 2016.

 
Link  NICE TA391: Cabazitaxel for hormone-relapsed metastatic prostate cancer treated with docetaxel
   
Cytotoxic Drug Paclitaxel
View adult BNF View SPC online View childrens BNF
Formulary

Red Traffic Light  For the treatment of ovarian cancer as per NICE TA55 and NICE TA389 (APCO May 2016).

Black Traffic Light  For the treatment of:

  • Adjuvant treatment of early node-positive breast cancer as per NICE TA108 (APCO November 2006).
  • First-line treatment of advanced ovarian cancer in combination with Bevacizumab and carboplatin as per NICE TA284 (APCO July 2013).
  • Other indications outside NICE.

 
Link  NICE TA108: Breast cancer (early) - paclitaxel
Link  NICE TA284:Bevacizumab in combination with paclitaxel and carboplatin for first-line treatment of advanced ovarian cancer
Link  NICE TA389 - Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer
Link  NICE TA55: Guidance on the use of paclitaxel in the treatment of ovarian cancer
   
Cytotoxic Drug Paclitaxel - Albumin Bound Formulation (Abraxane®)
View adult BNF View SPC online View childrens BNF
Formulary
High Cost Medicine

Red Traffic Light  In combination with gemcitabine for untreated metastatic pancreatic cancer as per NICE TA476 (APCO November 2017). Funded by specialised commissioning. 

Black Traffic Light  In combination with carboplatin for untreated non-small-cell lung cancer (NICE TA362 - terminated appraisal).

 
Link  NICE TA476: Paclitaxel as albumin-bound nanoparticles with gemcitabine for untreated metastatic pancreatic cancer
   
08.01.05  Expand sub section  Topoisomerase I inhibitors
Cytotoxic Drug Topotecan
View adult BNF View SPC online View childrens BNF
Formulary

Red Traffic Light  For the treatment of:

  • Relapsed small-cell lung cancer as per NICE TA184 (APCO January 2010).
  • Recurrent and stage IVB cervical canceras per NICE TA183 (APCO November 2009).


Black Traffic Light  For the treatment of recurrent ovarian cancer as per NICE TA389.

APCO May 2016.

 
Link  NICE TA183: Cervical cancer (recurrent) - topotecan
Link  NICE TA184: Lung cancer (small-cell) - topotecan
Link  NICE TA389 - Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer
   
08.01.05  Expand sub section  Trabectedin
Cytotoxic Drug Trabectedin (Yondelis®)
View adult BNF View SPC online View childrens BNF
Formulary

Red Traffic Light  For the treatment of advanced soft tissue sarcoma as per NICE TA185.

APCO March 2010.

Black Traffic Light  In combination with PLDH is not recommended for treating recurrent ovarian cancer as per NICE TA389.

APCO May 2016.

 
Link  NICE TA185: Soft tissue sarcoma - trabectedin
Link  NICE TA389 - Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer
   
08.01.05  Expand sub section  Trastuzumab
Cytotoxic Drug Pertuzumab (Perjeta®)
View adult BNF View SPC online View childrens BNF
Formulary
Red
High Cost Medicine
Cancer Drugs Fund
NHS England

For:

  • Neoadjuvant treatment of HER2-positive breast cancer as per NICE TA424 (APCO January 2017).
  • With trastuzumab and docetaxel for treating HER2-positive breast cancer as per NICE TA509 (APCO March 2018).
  • For adjuvant treatment of HER2-positive early stage breast cancer as per NICE TA569 (APCO May 2019). Funded by specialised commissioning. 
 
Link  NICE TA424: Pertuzumab for the neoadjuvant treatment of HER2-positive breast cancer
Link  NICE TA509: Pertuzumab with trastuzumab and docetaxel for treating HER2-positive breast cancer
Link  NICE TA569: Pertuzumab for adjuvant treatment of HER2-positive early stage breast cancer
Link  SMC advice (March 2016)
   
Cytotoxic Drug Trastuzumab (Herceptin®)
View adult BNF View SPC online View childrens BNF
Formulary
High Cost Medicine
Cancer Drugs Fund

Red Traffic Light  For the treatment of:

  • Advanced breast cancer as per NICE TA34
  • Early-stage HER2-positive breast cancer as per NICE TA107
  • HER2-positive metastatic gastric cancer as per NICE TA208 (APCO January 2011).
  • HER2-positive advanced breast cancer after trastuzumab and a taxane as per NICE TA458. (APCO September 2017).

Black Traffic Light  Not recommended for first-line treatment of metastatic hormone-receptor-positive breast cancer that overexpresses HER2 as per NICE TA257.

APCO July 2012.

 
Link  NICE TA208: Gastric cancer (HER2-positive metastatic) - trastuzumab
Link  NICE TA257: in combination with an aromatase inhibitor for HER2 positive metastatic breast cancer
Link  NICE TA34: Breast cancer - trastuzumab
Link  NICE TA458: Trastuzumab emtansine for treating HER2-positive advanced breast cancer after trastuzumab and a taxane
   
08.01.05  Expand sub section  Tretinoin to top
Tretinoin (Vesanoid®)
View adult BNF View SPC online View childrens BNF
Formulary
Red

Secondary care use only. 

APCO July 2008.

 
   
08.01.05  Expand sub section  Vismodegib
 ....
 Non Formulary Items
Cytotoxic Drug  Aflibercept  (Zaltrap®)

View adult BNF View SPC online View childrens BNF
Non Formulary
Black
High Cost Medicine
Cancer Drugs Fund

Not recommended in combination with irinotecan and fluorouracil-based therapy for treating metastatic colorectal cancer that is resistant to or has progressed after an oxaliplatin-containing regimen.

Not routinely commissioned by NHSE as per NICE TA307, CDIFR approval required.

APCO May 2014.

Link  NICE TA307: Aflibercept in combination with irinotecan and fluorouracil-based therapy for treating metastatic colorectal cancer that has progressed following prior oxaliplatin-based chemotherapy
Link  MHRA: Minimising the risk of osteonecrosis of the jaw
 
Cytotoxic Drug  Amsacrine  (Amsidine®)

View adult BNF View SPC online View childrens BNF
Non Formulary
 
Bexarotene  (Targretin®)

View adult BNF View SPC online View childrens BNF
Non Formulary
Black

Not recommended for cutaneous T-cell lymphoma.

APCO November 2010.

 
Cytotoxic Drug  Carboplatin

View adult BNF View SPC online View childrens BNF
Non Formulary
Black

Not recommended:

  • In combination with bevacizumab, paclitaxel, as first-line treatment for advanced ovarian cancer (including fallopian tube and primary peritoneal cancer) as per NICE TA284.
  • In combination with bevacizumab and gemcitabine for treating the first recurrence of platinum-sensitive advanced ovarian cancer as per NICE TA285.


APCO July 2013.

Link  NICE TA284: Bevacizumab in combination with paclitaxel and carboplatin for first-line treatment of advanced ovarian cancer
Link  NICE TA285: Bevacizumab in combination with gemcitabine and carboplatin for treating the first recurrence of platinum-sensitive advanced ovarian cancer
 
Cytotoxic Drug  Cisplatin

View adult BNF View SPC online View childrens BNF
Non Formulary
Cancer Drugs Fund
 
Cytotoxic Drug  Docetaxel  (Taxotere®)

View adult BNF View SPC online View childrens BNF
Non Formulary
Link  NICE TA101: Prostate cancer (hormone-refractory) - docetaxel
Link  NICE TA109: Breast cancer (early) - docetaxel
 
Elotuzumab  (Empliciti®)

View adult BNF View SPC online View childrens BNF
Non Formulary
Black

For previously treated multiple myeloma (NICE TA434 - terminated appraisal).

APCO May 2017. 

 
Cytotoxic Drug  Imatinib  (Gilvec®)
(600mg and 800mg)

View adult BNF View SPC online View childrens BNF
Non Formulary
Black
High Cost Medicine

Not recommended for treating imatinib-resistant or intolerant chronic myeloid leukaemia as per NICE TA425.

APCO January 2017.

Link  NICE TA425: Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia
 
Cytotoxic Drug  Irinotecan Hydrochloride  (Onivyde®)
(Pegylated liposomal)

View adult BNF View SPC online View childrens BNF
Non Formulary
Black

For treating:

  • Metastatic colorectal cancer that has progressed following prior oxaliplatin-based chemotherapy as per NICE TA307 (APCO May 2014).
  • Pancreatic cancer after gemcitabine as per NICE TA440 (APCO July 2017). 

Link  NICE TA307: Aflibercept in combination with irinotecan and fluorouracil-based therapy for treating metastatic colorectal cancer that has progressed following prior oxaliplatin-based chemotherapy
Link  NICE TA440: Pegylated liposomal irinotecan for treating pancreatic cancer after gemcitabine
 
Lapatinib  (Tyverb®)

View adult BNF View SPC online View childrens BNF
Non Formulary
Black
High Cost Medicine

Not recommended for in combination with an aromatase inhibitor for the first-line treatment of metastatic hormone-receptor-positive breast cancer that overexpresses HER2 as per NICE TA257.

APCO July 2012.

Link  NICE TA257: in combination with an aromatase inhibitor for HER2 positive metastatic breast cancer
 
Necitumumab  (Portrazza®)

View adult BNF View SPC online View childrens BNF
Non Formulary
Black
High Cost Medicine

Not recommended for untreated advanced or metastatic squamous non-small-cell lung cancer as per NICE TA411.

APCO November 2016.

Link  NICE TA411: Necitumumab for untreated advanced or metastatic squamous non-small-cell lung cancer
 
Pablociclib  (Ibrance®)

View adult BNF View SPC online View childrens BNF
Non Formulary
 
Padeliporfin  (Tookad®)

View adult BNF View SPC online View childrens BNF
Non Formulary
Black

Not recommended for untreated localised prostate cancer as per NICE TA546.

APCO January 2019.

Link  NICE TA546: Padeliporfin for untreated localised prostate cancer
 
Cytotoxic Drug  Panobinostat  (Farydak®)

View adult BNF View SPC online View childrens BNF
Non Formulary
High Cost Medicine
Link  NICE TA380: Panobinostat for treating multiple myeloma after at least 2 previous treatments
 
Porfimer Sodium  (Photofrin ®)

View adult BNF View SPC online View childrens BNF
Non Formulary
 
Ramucirumab  (Cyramza®)

View adult BNF View SPC online View childrens BNF
Non Formulary
Black
High Cost Medicine

Not recommended for:

    • Advanced gastric cancer or gastro–oesophageal junction adenocarcinoma previously treated with chemotherapy as per NICE TA378 (APCO March 2016).
    • Previously treated locally advanced or metastatic non-small-cell lung cancer as per NICE TA403 (APCO September 2016).
    • Unresectable hepatocellular carcinoma after sorafenib (terminated appraisal) as per NICE TA609 (APCO January 2020).

 

Link  NICE TA378: Ramucirumab for treating advanced gastric cancer or gastro–oesophageal junction adenocarcinoma previously treated with chemotherapy
Link  NICE TA403: Ramucirumab for previously treated locally advanced or metastatic non-small-cell lung cancer
Link  NICE TA609: Ramucirumab for treating unresectable hepatocellular carcinoma after sorafenib (terminated appraisal)
 
Rociletinib

View adult BNF View SPC online View childrens BNF
Non Formulary
 
Sonidegib  (Odomzo®)

View adult BNF View SPC online View childrens BNF
Non Formulary
 
Temoporfin  (Foscan®)

View adult BNF View SPC online View childrens BNF
Non Formulary
 
Cytotoxic Drug  Temsirolimus  (Torisel®)

View adult BNF View SPC online View childrens BNF
Non Formulary
Black
High Cost Medicine
Cancer Drugs Fund

Not recommended for:

  • Treatment of advanced and/or metastatic renal cell carcinomas per NICE TA178 (APCO September 2009).
  • Treatment of relapsed or refractory mantle cell lymphoma (NICE TA 207 - terminated appraisal). APCO November 2010.

Link  NICE TA178: Bevacizumab (first-line), sorafenib (first- and second-line), sunitinib (second-line) and temsirolimus (first-line) for the treatment of advanced and/or metastatic renal cell carcinoma
 
Cytotoxic Drug  Trastuzumab emtansine  (Kadcyla®)

View adult BNF View SPC online View childrens BNF
Non Formulary
Black
High Cost Medicine

For the treatment of HER2-positive, unresectable locally advanced or metastatic breast cancer after treatment with trastuzumab and a taxane as per NICE TA371.

APCO January 2016.

 
Cytotoxic Drug  Vandetanib  (Caprelsa®)

View adult BNF View SPC online View childrens BNF
Non Formulary
Black
High Cost Medicine
Cancer Drugs Fund

Not recommended for treating medullary thyroid cancer as per NICE TA550.

APCO January 2019.

Link  NICE TA550: Vandetanib for treating medullary thyroid cancer
 
Cytotoxic Drug  Vismodegib  (Erivedge®)

View adult BNF View SPC online View childrens BNF
Non Formulary
Black
High Cost Medicine

Not recommended within its marketing authorisation for treating symptomatic metastatic basal cell carcinoma, or locally advanced basal cell carcinoma that is inappropriate for surgery or radiotherapy as per NICE TA489.

APCO January 2018.

Link  NICE TA489: Vismodegib for treating basal cell carcinoma
 
Vosaroxin  (Qinprezo)

View adult BNF View SPC online View childrens BNF
Non Formulary
High Cost Medicine
 
  
Key
note Notes
Section Title Section Title (top level)
Section Title Section Title (sub level)
First Choice Item First Choice item
Non Formulary Item Non Formulary section
Restricted Drug
Restricted Drug
Unlicensed Drug
Unlicensed
Track Changes
Display tracking information
click to search medicines.org.uk
Link to adult BNF
click to search medicines.org.uk
Link to children's BNF
click to search medicines.org.uk
Link to SPCs
SMC
Scottish Medicines Consortium
Cytotoxic Drug
Cytotoxic Drug
CD
Controlled Drug
High Cost Medicine
High Cost Medicine
Cancer Drugs Fund
Cancer Drugs Fund
NHSE
NHS England
Homecare
Homecare
CCG
CCG

Traffic Light Status Information

Status Description

Red

Red: Medicines which should only be prescribed in secondary care by a specialist.  

Amber Continuation

Amber Continuation: Medicines which should be initiated or recommended by a specialist for continuation in primary care. The specialist must notify the GP that the prescribing responsibility has been transferred.   

Amber Shared Care Protocol

Amber Shared Care Protocol: Medicines which are appropriate to be initiated and stabilised by a specialist, once stabilised the medicine may be appropriate for responsibility to be transferred from secondary to primary care with the agreement of a GP and a formal ‘shared care’ agreement. The shared care protocol must be approved by the Area Prescribing Committee Oxfordshire (APCO).   

Green

Green: Medicines which are suitable for initiation and ongoing prescribing within primary care.   

Brown

Brown: Medicines which should only be prescribed in restricted circumstances.  

Black

Black: Medicines which are not recommended for use because of lack of evidence of clinical effectiveness, cost effectiveness or safety.  

OCCG Green

not used  

netFormulary